Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.

BMC Cancer · 2016 · PMC4990870 · PMID 27538465

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a pronounced trendno p-value reported

The surviving patient had a pronounced trend for gradually improving adaptive immunity whereas T-reg population was significantly reduced.

also in 237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.